Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989676 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29989746 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL13946516 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30082405 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL1253102 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29401317 | 1.00 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL2033787 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL5260936 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30229677 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL20299891 | 0.91 | MDM4 (0.54) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20240374585-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | REIN THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-12084455-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4367129-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | Lung Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20240082410-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2024-03-14 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20150238558-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-20150164974-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
| US-8889712-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2776409-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | Ensemble Therapeutics (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2014074658-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-15 | — | — | US | disclosed |
| US-20130338081-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2013-12-19 | — | — | US | disclosed |
| WO-2013071027-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071035-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | API5, BIRC5, BAD | CASP3 12/4885MDM4 424/4885TP53 45/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | CASP3 2604/4885MDM4 3644/4885TP53 3936/4885 |
| US-12084455-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | CASP3 2604/4885MDM4 3644/4885TP53 3936/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | CASP3 3268/4885MDM4 1294/4885TP53 178/4885 |
| US-20150164974-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | CASP3 18/4885MDM4 919/4885TP53 21/4885 |
| US-20240082410-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | CASP3 1178/4885MDM4 2089/4885TP53 826/4885 |
| US-20130338081-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | CASP3 18/4885MDM4 919/4885TP53 21/4885 |
| US-20240374585-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | CFTR, SCNN1G, SCNN1B | CASP3 4149/4885MDM4 4858/4885TP53 3648/4885 |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | CASP3 2604/4885MDM4 3644/4885TP53 3936/4885 |
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BAX, API5, BCL2 | CASP3 8/4885MDM4 894/4885TP53 34/4885 |
| US-20150238558-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | CASP3 18/4885MDM4 919/4885TP53 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.